| Title | Authors / Editors | Date |
unige:13281 |
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles |
Cirstoiu, Adriana; Bossy-Nobs, L.; Buchegger, Franz; Gurny, Robert; Delie Salmon, Florence |
2007 |
unige:21118 |
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98 |
Martinelli, Giovanni; Schmitz, Shu-Fang Hsu; Utiger, Urs; Cerny, Thomas; ... Ghielmini, Michele |
2010 |
unige:55974 |
Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission |
Ozsahin, Ayse Hulya; Fluss, Joel Victor; Mclin, Valérie Anne; Wacker, Pierre; ... Helg, Claudine |
2002 |
unige:45722 |
Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients |
Berney, Thierry; Delis, Spiros; Kato, Tomoaki; Nishida, Seigo; ... Tzakis, Andreas G |
2002 |
unige:35025 |
Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab |
Hristea, Dan; Hadaya, Karine; Marangon, Nicola Danièle Armando; Buehler, Leo Hans; ... Martin, Pierre-Yves |
2007 |
unige:19810 |
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? |
Finckh, Axel; Ciurea, A.; Brulhart, L.; Moller, B.; ... Gabay, Cem |
2010 |